MIRA Pharmaceuticals, Inc. (MIRA)

NCM – Real Time Price. Currency in USD

0.74

-0.03 (-4.23%)

Market open: Aug 12, 2026, 1:51 PM EDT

0.79

+0.01 (1.54%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1 in Beagle dogs. The study demonstrates dose-dependent systemic exposure and rapid absorption that de-risk dose selection and support advancement toward GLP toxicology studies and IND-enabling development.

Videos

No Data

There is no data to display

Press releases

06.08.2026

MIRA Pharmaceuticals, Inc. (MIRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Videos

No Data

Press releases

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Videos

No Data

Press releases

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Search stocks

MIRA Pharmaceuticals, Inc. (MIRA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Videos

No Data

Press releases

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

Videos

No Data

Press releases

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1